VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 87 filers reported holding VAXCYTE INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $717,647,365 | +2.2% | 14,077,037 | +0.1% | 0.06% | +5.1% |
Q2 2023 | $701,968,411 | -20.7% | 14,056,236 | -40.5% | 0.06% | +47.5% |
Q1 2023 | $885,170,052 | +81.5% | 23,617,130 | +132.2% | 0.04% | -16.7% |
Q4 2022 | $487,617,048 | +128.4% | 10,169,282 | +14.3% | 0.05% | +118.2% |
Q3 2022 | $213,533,000 | +15.3% | 8,897,197 | +4.5% | 0.02% | +22.2% |
Q2 2022 | $185,253,000 | -8.4% | 8,513,406 | +1.6% | 0.02% | +12.5% |
Q1 2022 | $202,304,000 | +8.0% | 8,376,942 | +6.4% | 0.02% | +14.3% |
Q4 2021 | $187,331,000 | -5.7% | 7,874,350 | +0.6% | 0.01% | -12.5% |
Q3 2021 | $198,605,000 | +14.5% | 7,828,385 | +1.6% | 0.02% | +14.3% |
Q2 2021 | $173,480,000 | +14.1% | 7,706,809 | +0.1% | 0.01% | +7.7% |
Q1 2021 | $152,059,000 | -25.1% | 7,699,143 | +0.7% | 0.01% | -27.8% |
Q4 2020 | $203,058,000 | -35.5% | 7,642,405 | +19.9% | 0.02% | -43.8% |
Q3 2020 | $314,836,000 | +111.6% | 6,375,763 | +35.5% | 0.03% | +100.0% |
Q2 2020 | $148,780,000 | – | 4,706,759 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |